fda warning letters glp-1 compounders september 2025 news issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's crackdown on misleading pharmaceutical ads From Crackdown to Collaboration: FDA

Session 8 Lower Body Integration Weave together feet, knees, hips, and pelvis so walking feels coordinated and efficient in your lighter body

Individuals with a history of pancreatitis may need a different treatment plan

BPC-157 upregulates survival genes (Akt1, KRAS, Src, Foxo1), reduces inflammatory mediators (IL-6, TNF-, NOS2, NFB), scavenges reactive oxygen species through its four carboxylic groups, activates vascular bypass pathways, and maintains blood flow despite vessel occlusion

long-acting analogs such as cagrilintide are widely investigated in obesity and metabolic research, frequently alongside GLP-1 receptor agonists

References Centers for Medicare & Medicaid Services